Please assess the completion status of the following clinical trial:

Trial Title: Saline Hypertonic in Preschoolers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:~* A documented sweat chloride ≥ 60 milliequivalents of solute per litre (mEq/L) by quantitative pilocarpine iontophoresis (QPIT)~* A documented genotype with two disease-causing mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene~* Informed consent by parent or legal guardian~* Age ≥ 36 months and ≤72 months at Screening visit~* Ability to comply with medication use, study visits and study procedures as judged by the site investigator~* Ability to perform technically acceptable MBW measurements at the screening and enrollment visits~Exclusion Criteria:~* Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding Screening or Enrollment visit~* Acute wheezing at Screening or Enrollment visit~* Oxygen saturation \< 95% (\<90% in centers located above 4000 feet elevation) at Screening or Enrollment visit~* Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator~* Investigational drug use within 30 days prior to Screening or Enrollment visit~* Treatment with inhaled hypertonic saline at any concentration within 30 days prior to Screening or Enrollment visit~* Chronic lung disease not related to CF~* Inability to tolerate first dose of study treatment at the Enrollment visit

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment Group (Type: EXPERIMENTAL): 7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
- Control Group (Type: ACTIVE_COMPARATOR): 0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).